8/24/2005. Two publicly traded Japanese drugmakers have teamed up with an investment vehicle that will aim to invest in American and European anticancer start-ups. Daiichi Pharmaceutical Co. Ltd. and MediBic Alliance Co. Ltd. plan to put roughly Y700 million ($6.4 million) into what Ari Zarah, a member of the MediBic investment team described as a “very focused fund.”
